RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/19305397http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19305397http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19305397http://www.w3.org/2000/01/rdf-schema#comment"Fragment screens have successfully identified new scaffolds in drug discovery, often with relatively high hit rates (5%) using small screening libraries (1,000-10,000 compounds). This raises two questions: would other noteworthy chemotypes be found were one to screen all commercially available fragments (>300,000), and does the success rate imply low specificity of fragments? We used molecular docking to screen large libraries of fragments against CTX-M beta-lactamase. We identified ten millimolar-range inhibitors from the 69 compounds tested. The docking poses corresponded closely to the crystallographic structures subsequently determined. Notably, these initial low-affinity hits showed little specificity between CTX-M and an unrelated beta-lactamase, AmpC, which is unusual among beta-lactamase inhibitors. This is consistent with the idea that the high hit rates among fragments correlate to a low initial specificity. As the inhibitors were progressed, both specificity and affinity rose together, yielding to our knowledge the first micromolar-range noncovalent inhibitors against a class A beta-lactamase."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.org/dc/terms/identifier"doi:10.1038/nchembio.155"xsd:string
http://purl.uniprot.org/citations/19305397http://purl.org/dc/terms/identifier"doi:10.1038/nchembio.155"xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/author"Chen Y."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/author"Chen Y."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/author"Shoichet B.K."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/author"Shoichet B.K."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/date"2009"xsd:gYear
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/date"2009"xsd:gYear
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/name"Nat. Chem. Biol."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/name"Nat Chem Biol"xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/pages"358-364"xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/pages"358-364"xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/title"Molecular docking and ligand specificity in fragment-based inhibitor discovery."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/title"Molecular docking and ligand specificity in fragment-based inhibitor discovery."xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/volume"5"xsd:string
http://purl.uniprot.org/citations/19305397http://purl.uniprot.org/core/volume"5"xsd:string
http://purl.uniprot.org/citations/19305397http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19305397
http://purl.uniprot.org/citations/19305397http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19305397
http://purl.uniprot.org/citations/19305397http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/19305397
http://purl.uniprot.org/citations/19305397http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/19305397
http://purl.uniprot.org/uniprot/Q9L5C8http://purl.uniprot.org/core/citationhttp://purl.uniprot.org/citations/19305397
http://purl.uniprot.org/uniprot/#_Q9L5C8-citation-19305397http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19305397